| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G |
| 13 Nov 2026 | SCHEDULE 13G/A |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
On track to report initial Phase 1 data from HWK-007 and HWK-016 in 1H’27 |
| 18 Sep 2026 |
Form 4/A: Giacobello Scott M., CHIEF FINANCIAL OFFICER
Granted 118,476 Stock Option (right to buy) · Granted 118,476 Restricted Stock Units |
| 18 Sep 2026 |
Form 4/A: Ball Bryan, See remarks
Granted 91,633 Stock Option (right to buy) · Granted 91,633 Restricted Stock Units |
| 18 Sep 2026 |
Form 4/A: Dornan David, Chief Scientific Officer
Granted 85,887 Stock Option (right to buy) · Granted 85,887 Restricted Stock Units |
| 18 Sep 2026 |
Form 4/A: Lennon David James, Director
Granted 193,957 Stock option (right to buy) · Granted 193,957 Restricted Stock Units |
| 18 Sep 2026 |
Form 4/A: Dugan Margaret, Chief Medical Officer
Granted 81,250 Stock Option (right to buy) · Granted 81,250 Restricted Stock Units |
| 15 Sep 2026 |
Form 4: Lennon David James, Director
Granted 193,957 Stock option (right to buy) · Granted 193,957 Restricted Stock Units |
| 15 Sep 2026 |
Form 4: Giacobello Scott M., CHIEF FINANCIAL OFFICER
Granted 118,476 Stock Option (right to buy) · Granted 118,476 Restricted Stock Units |
| 15 Sep 2026 |
Form 4: Dugan Margaret, Chief Medical Officer
Granted 81,250 Stock Option (right to buy) · Granted 81,250 Restricted Stock Units |
| 15 Sep 2026 |
Form 4: Dornan David, Chief Scientific Officer
Granted 85,887 Stock Option (right to buy) · Granted 85,887 Restricted Stock Units |
| 15 Sep 2026 |
Form 4: Ball Bryan, See remarks
Granted 91,633 Stock Option (right to buy) · Granted 91,633 Restricted Stock Units |
| 11 Sep 2026 |
Form 4: Iyengar Vijay K, Director
Granted 76,080 Stock Option (right to buy) |
| 11 Sep 2026 |
Form 3: Iyengar Vijay K, Director
No securities owned |
| 10 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Former Incyte Executive Brings Extensive Oncology, Corporate Strategy, Business Development and Medical Affairs Experience |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
Loading...